Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AND014
MIFTS: 46

Androgenic Alopecia

Categories: Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Androgenic Alopecia

About this section

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia 11 14 75 31
Androgenetic Alopecia 11 71
Alopecia Androgenetica, Male Pattern Baldness 11

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:0050801
ICD10 31 L64 L64.9
UMLS 71 C0162311
Sources

Summaries for Androgenic Alopecia

About this section

Disease Ontology: 11 An alopecia that is characterized by M-shaped hair line recession and thinning of hair at the crown of the head in males.

MalaCards based summary: Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and alopecia. An important gene associated with Androgenic Alopecia is SRD5A2 (Steroid 5 Alpha-Reductase 2), and among its related pathways/superpathways are Signal Transduction and Nanog in Mammalian ESC Pluripotency. The drugs Acetylcysteine and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and ovary, and related phenotypes are endocrine/exocrine gland and renal/urinary system
Sources

Related Diseases for Androgenic Alopecia

About this section

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 32.7 SRD5A2 SRD5A1 SHBG AR
2 alopecia 31.0 SRD5A2 SRD5A1 SHBG PRL KRT15 IGF1
3 prostatic hyperplasia, benign 30.7 SRD5A2 SRD5A1 FGF7 AR
4 gynecomastia 30.6 SRD5A2 SRD5A1 SHBG PRL AR
5 polycystic ovary syndrome 30.5 SRD5A1 SHBG PRL INS IGF1 AR
6 galactorrhea 30.4 PRL IGF1
7 prostatic hypertrophy 30.3 SRD5A2 SHBG INS IGF1 AR
8 hyperprolactinemia 30.3 SHBG PRL INS IGF1
9 androgen insensitivity syndrome 30.3 SRD5A2 SRD5A1 SHBG AR
10 acne 30.3 SRD5A1 SHBG PRL INS IGF1 AR
11 hyperandrogenism 30.2 SRD5A1 SHBG PRL INS IGF1 AR
12 impotence 30.1 VEGFA SRD5A1 SHBG PRL AR
13 hypogonadism 30.0 SHBG PRL INS IGF1 AR
14 hypogonadotropic hypogonadism 29.9 SRD5A2 SHBG PRL INS IGF1 AR
15 insulin-like growth factor i 29.9 VEGFA SHBG PRL INS IGF1
16 skin disease 29.9 VEGFA SRD5A1 INS IGF1 FGF7 CTNNB1
17 hypothyroidism 29.8 VEGFA SHBG PRL INS IGF1
18 lipoid congenital adrenal hyperplasia 29.7 SRD5A2 SRD5A1 SHBG PRL INS IGF1
19 premature menopause 29.6 VEGFA SRD5A2 SHBG PRL INS IGF1
20 telogen effluvium 29.6 VCAN SRD5A2 SHBG PRL IGF1 FGF7
21 ovarian disease 29.6 VEGFA SHBG PRL INS IGF1 CTNNB1
22 hair disease 29.4 VEGFA SRD5A2 SHBG KRT15 INS IGF1
23 prostate cancer 29.3 VEGFA TMPRSS2 SRD5A2 SRD5A1 SHBG LEF1
24 hypertension, essential 29.2 VEGFA TMPRSS2 SHBG PRL INS IGF1
25 diabetes mellitus 29.2 VEGFA SHBG PRL INS IGF1 CTNNB1
26 hypotrichosis 1 11.1
27 hypotrichosis simplex 11.1
28 rapidly involuting congenital hemangioma 10.6
29 frontal fibrosing alopecia 10.5
30 covid-19 10.5
31 seborrheic dermatitis 10.5
32 alopecia areata 10.4
33 gender incongruence 10.3 SRD5A2 SHBG AR
34 prostatic acinar adenocarcinoma 10.3 TMPRSS2 AR
35 complete androgen insensitivity syndrome 10.3 SRD5A2 SHBG AR
36 inhibited female orgasm 10.3 SHBG PRL
37 penis agenesis 10.3 SRD5A2 SRD5A1 AR
38 epilepsy, idiopathic generalized 4 10.3 INS AR
39 retroperitoneal hemangiopericytoma 10.3 INS IGF1
40 liver lipoma 10.3 INS CTNNB1
41 hypoactive sexual desire disorder 10.3 SHBG PRL
42 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.3 INS IGF1
43 prolactin producing pituitary tumor 10.3 PRL IGF1
44 polycystic ovary syndrome 1 10.3
45 hair whorl 10.3
46 nephrolithiasis, calcium oxalate 10.3
47 coronary heart disease 1 10.3
48 urolithiasis 10.3
49 conn's syndrome 10.3
50 dermatitis 10.3

Graphical network of the top 20 diseases related to Androgenic Alopecia:



Diseases related to Androgenic Alopecia
Sources

Symptoms & Phenotypes for Androgenic Alopecia

About this section

GenomeRNAi Phenotypes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ACE2 AR CTNNB1 DKK1 EDA2R FGF5
2 no effect GR00402-S-2 10.19 AR CTNNB1 DKK1 EDA2R FGF7 IGF1

MGI Mouse Phenotypes related to Androgenic Alopecia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.06 AR CTNNB1 IGF1 INS LEF1 PRL
2 renal/urinary system MP:0005367 10.03 ACE2 AR CTNNB1 DKK1 FGF7 IGF1
3 limbs/digits/tail MP:0005371 10.02 AR CTNNB1 DKK1 FGF7 IGF1 LEF1
4 muscle MP:0005369 10.01 ACE2 AR CTNNB1 IGF1 INS TMPRSS2
5 reproductive system MP:0005389 9.9 AR CTNNB1 FGF7 IGF1 INS LEF1
6 digestive/alimentary MP:0005381 9.86 ACE2 AR CTNNB1 INS KRT15 VEGFA
7 skeleton MP:0005390 9.65 AR CTNNB1 DKK1 IGF1 INS LEF1
8 integument MP:0010771 9.4 ACE2 AR CTNNB1 FGF5 FGF7 IGF1
Sources

Drugs & Therapeutics for Androgenic Alopecia

About this section

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
2
Cetirizine Approved Phase 4 83881-51-0 2678
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
5 N-monoacetylcystine Phase 4
6 Anti-Allergic Agents Phase 4
7
Histamine phosphate Phase 4 51-74-1 134614
8 Histamine H1 Antagonists, Non-Sedating Phase 4
9 Histamine H1 Antagonists Phase 4
10 Histamine Antagonists Phase 4
11 Anti-Infective Agents Phase 4
12
Dutasteride Approved, Investigational Phase 3 164656-23-9 6918296
13
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
14
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
15
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
16
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
17
Dinoprost tromethamine Approved, Vet_approved Phase 1, Phase 2 38562-01-5
18
Dinoprost Approved, Investigational Phase 1, Phase 2 551-11-1 5283078 5280363
19
Ascorbic acid Approved, Nutraceutical Phase 1, Phase 2 50-81-7 54676860 54670067 5785
20
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-16-7, 110-17-8 444266 444972
21 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
22 Antiviral Agents Phase 2
23 Radiation-Protective Agents Phase 2
24 Adjuvants, Immunologic Phase 2
25 Reverse Transcriptase Inhibitors Phase 2
26 Immunologic Factors Phase 2
27 Protective Agents Phase 2
28 Bronchodilator Agents Phase 1, Phase 2
29 Anti-Asthmatic Agents Phase 1, Phase 2
30 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
31 Respiratory System Agents Phase 1, Phase 2
32 Antioxidants Phase 1, Phase 2
33 Pharmaceutical Solutions Phase 2
34 Androgens Phase 2
35 Neurotransmitter Agents Phase 2
36 HIV Protease Inhibitors Phase 2
37 Proteasome Inhibitors Phase 2
38
protease inhibitors Phase 2
39
abobotulinumtoxinA Phase 2
40 Botulinum Toxins, Type A Phase 2
41 Cholinergic Agents Phase 2
42 Ophthalmic Solutions Phase 2
43 Psychotropic Drugs Phase 2
44 Anticonvulsants Phase 2
45 Botulinum Toxins Phase 2
46
incobotulinumtoxinA Phase 2
47 Anesthetics Phase 1
48 Androgen Receptor Antagonists Phase 1
49
Roxithromycin Approved, Investigational, Withdrawn 80214-83-1 6915744
50
Cyproterone acetate Approved, Investigational 427-51-0 9880

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Unknown status NCT03388840 Phase 4
2 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Unknown status NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
3 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Unknown status NCT04293822 Phase 4 Cetirizine;Minoxidil
4 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
5 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
6 The Use of Hydradermabrasion in the Scalp to Improve Scalp Health and Improve Outcomes in Androgenetic Alopecia Recruiting NCT05426629 Phase 4
7 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
8 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
9 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
10 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical vehicle solution
11 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
12 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
13 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
14 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
15 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
16 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
17 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
18 Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial Completed NCT05296863 Phase 3
19 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
20 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
21 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
22 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
23 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia Recruiting NCT04825561 Phase 3 AD-208;AD-2081;placebo of AD-208;placebo of AD-2081
24 The Role of Cetirizine in Androgenetic Alopecia in Females Active, not recruiting NCT04481412 Phase 2, Phase 3 Topical cetirizine;Placebo;Topical minoxidil
25 A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male Patients With Androgenetic Alopecia (AGA) Active, not recruiting NCT05135468 Phase 3 CU-40102 Spray
26 National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia. Not yet recruiting NCT04594018 Phase 3 Finlândia Association + finasteride placebo;Minoxidil + finasteride
27 A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks Not yet recruiting NCT04721548 Phase 3 Minoxidil Topical Foam;Placebo
28 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
29 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
30 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradomeâ„¢ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
31 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
32 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
33 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
34 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
35 A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers Completed NCT03467412 Phase 2 FOL-005;Placebo
36 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
37 A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women Completed NCT03488108 Phase 1, Phase 2 Minoxidil Foam
38 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
39 Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02150187 Phase 2
40 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
41 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
42 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
43 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
44 A Randomized, Double-blind, Vehicle-controlled, Dose-finding Multi-center, Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers With Androgenetic Alopecia Completed NCT04774874 Phase 2 Topical formulation
45 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
46 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
47 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
48 An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Completed NCT03495817 Phase 2 ATI-50002
49 Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
50 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2

Search NIH Clinical Center for Androgenic Alopecia

Sources

Genetic Tests for Androgenic Alopecia

About this section
Sources

Anatomical Context for Androgenic Alopecia

About this section

Organs/tissues related to Androgenic Alopecia:

MalaCards : Skin, Prostate, Ovary, Adipocyte, Brain, Breast, Endothelial
Sources

Publications for Androgenic Alopecia

About this section

Articles related to Androgenic Alopecia:

(show top 50) (show all 2361)
# Title Authors PMID Year
1
Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia. 62
36199226 2022
2
A Comprehensive Review of Microneedling as a Potential Treatment Option for Androgenetic Alopecia. 62
35930041 2022
3
Dendrobium officinale Polysaccharide (DOP) Promotes Hair Regrowth in Testosterone-Induced Bald Mice. 62
36470987 2022
4
Telemedical care of men with androgenetic alopecia demonstrates improved access to care and patient benefit. 62
35841293 2022
5
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways. 62
35862273 2022
6
Microneedle mediated transdermal delivery of β-sitosterol loaded nanostructured lipid nanoparticles for androgenic alopecia. 62
36110028 2022
7
Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. 62
36382136 2022
8
Application of lncRNA-miRNA-mRNA ceRNA network analysis in the treatment of androgenic alopecia. 62
36458379 2022
9
Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia. 62
35040730 2022
10
Female pattern hair loss and polycystic ovarian syndrome: more than just hirsutism. 62
36226726 2022
11
Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics. 62
36460729 2022
12
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. 62
35341398 2022
13
Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman. 62
36409990 2022
14
Androgens' Role in Severity and Mortality Rates of COVID-19. 62
36195265 2022
15
A Comprehensive Review of Platelet-Rich Plasma in the Treatment of Dermatologic Disorders. 62
36318219 2022
16
PCOS and Depression: Common Links and Potential Targets. 62
34642910 2022
17
Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia? 62
34716575 2022
18
Comprehensive transcriptome data to identify downstream genes of testosterone signalling in dermal papilla cells. 62
36446804 2022
19
Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia. 62
35603693 2022
20
Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil. 62
36319878 2022
21
The efficacy of LED microneedle patch on hair growth in mice. 62
36416978 2022
22
The physiological and pharmacological roles of prostaglandins in hair growth. 62
36302616 2022
23
In silico screening of effective inhibitor of 5α-reductase type 1 for androgenic alopecia treatment. 62
34937445 2022
24
Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? 62
35881665 2022
25
Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. 62
35389034 2022
26
Ablative 2940 nm Er: YAG fractional laser for male androgenetic alopecia. 62
36043547 2022
27
Machine Learning Guided Discovery of Superoxide Dismutase Nanozymes for Androgenetic Alopecia. 62
36264822 2022
28
Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. 62
35920739 2022
29
Evaluating the Efficacy of Platelet Rich Plasma and 1550 nm Fractional Laser in Combination and Alone for the Management of Androgenetic Alopecia. 62
36342732 2022
30
Efficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment of Androgenetic Alopecia. 62
36352823 2022
31
The efficacy and safety of the combination of photobiomodulation therapy and pulsed electromagnetic field therapy on androgenetic alopecia. 62
36345917 2022
32
Reply to: Platelet-rich plasma application by dermapen microneedling and intradermal point-by-point injection methods, and their comparison with clinical findings and Trichoscan in patients with androgenetic alopecia. 62
36109350 2022
33
The effect of COVID-19 on development of hair and nail disorders: a Turkish multicenter, controlled study. 62
36281828 2022
34
Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. 62
36264022 2022
35
Serum Ferritin Levels amongst Individuals with Androgenetic Alopecia in Ile-Ife, Nigeria. 62
36260427 2022
36
An assessment for measuring loneliness, anxiety, and depression in male patients with androgenetic alopecia undergoing hair transplantation surgery: A before-after study. 62
36217686 2022
37
Comparison of Efficacy of Platelet-Rich Plasma (PRP) With PRP Microneedling in Androgenetic Alopecia. 62
36407242 2022
38
Comorbidities in Androgenetic Alopecia: A Comprehensive Review. 62
36115913 2022
39
Digital health platforms expand access and improve care for male androgenetic alopecia. 62
36250302 2022
40
Comparison between "5% minoxidil plus 2% flutamide" solution vs. "5% minoxidil" solution in the treatment of androgenetic alopecia. 62
35152531 2022
41
Efficacy of botulinum toxin A injection in the treatment of androgenic alopecia: A Comparative Controlled Study. 62
35100493 2022
42
Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. 62
35648446 2022
43
The comparison of demographics and comorbidities of female pattern hair loss according to the clinical subtype and stage. 62
34838685 2022
44
Cross-Sectional Study of Trichoscopy Features, Prevalence, Types of Hair Loss and Hair Care Practices at a Lagos Urban Market. 62
36260091 2022
45
Conditioned media-integrated microneedles for hair regeneration through perifollicular angiogenesis. 62
35961471 2022
46
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia. 62
36222207 2022
47
Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. 62
36386264 2022
48
Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study. 62
36198626 2022
49
A Survey of Patient Attitudes Towards Topical Minoxidil in the Treatment of Hair Loss. 62
36219050 2022
50
Invasive cutaneous squamous cell carcinoma of scalp: A case report. 62
36268452 2022
Sources

Variations for Androgenic Alopecia

About this section
Sources

Expression for Androgenic Alopecia

About this section
Search GEO for disease gene expression data for Androgenic Alopecia.
Sources

Pathways for Androgenic Alopecia

About this section

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.61 WNT10B WNT10A VEGFA LEF1 INS IGF1
2
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.13 WNT10B WNT10A VEGFA LEF1 IGF1 FGF7
3
PI3K-Akt signaling pathway 74
Show member pathways
 12.86 VEGFA PRL INS IGF1 FGF7 FGF5
4
Signaling by WNT 66
Show member pathways
 12.8 WNT10B WNT10A LEF1 DKK1 CTNNB1
5
Alzheimer's disease and miRNA effects 74
Show member pathways
 12.77 WNT10B WNT10A INS DKK1 CTNNB1
6
ncRNAs involved in Wnt signaling in hepatocellular carcinoma 74
Show member pathways
 12.74 WNT10B WNT10A LEF1 DKK1 CTNNB1
7
Signaling by Receptor Tyrosine Kinases 66
12.72 CTNNB1 FGF5 FGF7 IGF1 INS VEGFA
8
Human Embryonic Stem Cell Pluripotency 64
Show member pathways
 12.38 WNT10B WNT10A LEF1 DKK1 CTNNB1
9
WNT Signaling 64
12.34 WNT10B WNT10A LEF1 DKK1 CTNNB1
10
Breast cancer pathway 74
Show member pathways
 12.13 WNT10B WNT10A LEF1 IGF1 FGF7 FGF5
11
Peptide hormone metabolism 66
Show member pathways
 12.12 INS IGF1 CTNNB1 ACE2
12
Colorectal Cancer Metastasis 64
12.05 WNT10B WNT10A VEGFA LEF1 CTNNB1
13
Adipogenesis 74
11.99 WNT10B INS IGF1 CTNNB1
14
Wnt Pathway 70
Show member pathways
 11.93 WNT10B WNT10A DKK1 CTNNB1
15
Malignant pleural mesothelioma 74
11.93 WNT10B WNT10A VEGFA LEF1 INS IGF1
16
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 65
11.84 VEGFA INS IGF1 FGF7 DKK1
17
DNA damage response (only ATM dependent) 74
11.82 WNT10B WNT10A LEF1 CTNNB1
18
Overlap between signal transduction pathways contributing to LMNA laminopathies 74
Show member pathways
 11.8 WNT10B LEF1 CTNNB1
19
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.77 WNT10B VCAN INS IGF1
20
Clock-controlled autophagy in bone metabolism 74
11.73 WNT10B IGF1 DKK1
21
Endoderm differentiation 74
11.66 LEF1 DKK1 CTNNB1
22
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.66 WNT10B WNT10A SRD5A2 SRD5A1 IGF1 CTNNB1
23
Coregulation of Androgen receptor activity 61
11.58 TMPRSS2 CTNNB1 AR
24
Non-Canonical Wnt Pathway 67
11.56 WNT10A LEF1 CTNNB1
25
Cardiac progenitor differentiation 74
11.51 DKK1 IGF1 INS
26
Regulation of nuclear beta catenin signaling and target gene transcription 61
11.51 VCAN LEF1 DKK1 CTNNB1 AR
27
Canonical Wnt Pathway 67
11.4 CTNNB1 DKK1 LEF1 WNT10A
28
Vemurafenib Pathway, Pharmacodynamics 60
11.39 VEGFA FGF7 FGF5
29
Pluripotent stem cell differentiation pathway 74
11.35 VEGFA INS IGF1 DKK1
30
SARS-CoV-2 and COVID-19 pathway 74
10.64 TMPRSS2 ACE2
31
COVID-19 adverse outcome pathway 74
10.64 TMPRSS2 ACE2
32
Glypican 3 network 61
10.53 FGF7 DKK1
33
SARS-CoV-2 altering angiogenesis via NRP1 74
10.3 VEGFA ACE2
Sources

GO Terms for Androgenic Alopecia

About this section

Cellular components related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10 WNT10B WNT10A VEGFA VCAN PRL INS
2 extracellular region GO:0005576 9.74 ACE2 DKK1 FGF5 FGF7 IGF1 INS
3 cell body fiber GO:0070852 9.46 SRD5A2 SRD5A1

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 osteoblast differentiation GO:0001649 10.08 WNT10B VCAN LEF1 CTNNB1
2 epithelial to mesenchymal transition GO:0001837 10.06 LEF1 IGF1 CTNNB1
3 positive regulation of MAPK cascade GO:0043410 10.06 AR CTNNB1 IGF1 INS VEGFA
4 positive regulation of cell division GO:0051781 10.05 VEGFA FGF7 FGF5
5 hair follicle morphogenesis GO:0031069 9.99 WNT10A FGF7 CTNNB1
6 branching involved in blood vessel morphogenesis GO:0001569 9.97 VEGFA LEF1 CTNNB1
7 positive regulation of cell differentiation GO:0045597 9.97 LEF1 INS CTNNB1 AR
8 male genitalia development GO:0030539 9.91 SRD5A2 SRD5A1 CTNNB1
9 regulation of transmembrane transporter activity GO:0022898 9.89 INS ACE2
10 positive regulation of cell population proliferation GO:0008284 9.89 AR CTNNB1 FGF5 FGF7 IGF1 INS
11 response to follicle-stimulating hormone GO:0032354 9.87 SRD5A2 SRD5A1
12 female genitalia development GO:0030540 9.86 SRD5A2 SRD5A1
13 cell morphogenesis involved in differentiation GO:0000904 9.85 DKK1 CTNNB1
14 Wnt signaling pathway GO:0016055 9.85 WNT10B WNT10A LEF1 DKK1 CTNNB1
15 canonical Wnt signaling pathway GO:0060070 9.85 WNT10B WNT10A LEF1 DKK1 CTNNB1
16 epithelial cell differentiation involved in prostate gland development GO:0060742 9.83 AR CTNNB1
17 myoblast proliferation GO:0051450 9.8 IGF1 FGF7 CTNNB1
18 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.78 CTNNB1 AR
19 hypothalamus development GO:0021854 9.73 CTNNB1 SRD5A1 SRD5A2
20 positive regulation of gene expression GO:0010628 9.62 WNT10A VEGFA LEF1 INS IGF1 FGF7

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen binding GO:0005497 9.62 SHBG AR
2 cholestenone 5-alpha-reductase activity GO:0047751 9.56 SRD5A2 SRD5A1
3 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.46 SRD5A2 SRD5A1
4 growth factor activity GO:0008083 9.32 VEGFA IGF1 FGF7 FGF5 DKK1
5 amide binding GO:0033218 9.26 SRD5A2 SRD5A1
Sources

Sources for Androgenic Alopecia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....